Hyperbaric oxygen therapy reduces ME/CFS fatigue, brain fog and neuroinflammation
Hyperbaric oxygen therapy reduces ME/CFS fatigue, brain fog and neuroinflammation
Understanding ME/CFS and how HBOT addresses its core neurological mechanisms
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a complex, debilitating multisystem illness characterized by severe, persistent fatigue not relieved by rest, post-exertional malaise, cognitive impairment, orthostatic intolerance and unrefreshing sleep. It affects an estimated 1 to 2.5 million Americans and has no FDA-approved disease-modifying treatment.
For decades ME/CFS was mischaracterized as a psychiatric condition, but a growing body of research has established its organic physiological basis. Neuroimaging studies using PET and SPECT have consistently demonstrated reduced cerebral blood flow in ME/CFS patients. Post-mortem and in vivo neuroimaging studies have found evidence of neuroinflammation in key brain regions. Metabolomics research has documented widespread mitochondrial dysfunction and impaired cellular energy metabolism. Post-COVID ME/CFS research has accelerated understanding of the condition's mechanisms substantially.
HBOT addresses several of the core physiological abnormalities identified in ME/CFS: it increases cerebral oxygen delivery to hypoperfused brain regions, suppresses neuroinflammation through anti-inflammatory cytokine modulation, stimulates mitochondrial biogenesis and improves ATP production. An important randomized controlled trial from Israel published in 2021 demonstrated significant improvements in cognitive function, pain and quality of life in fibromyalgia patients — a closely overlapping condition — with concurrent neuroimaging showing objective improvements in brain blood flow.
Profound, persistent fatigue not relieved by rest, lasting more than 6 months
Post-exertional malaise — worsening of all symptoms after physical or cognitive exertion
Cognitive impairment including brain fog, memory difficulties and slowed processing
Unrefreshing sleep and sleep disturbances
Orthostatic intolerance — symptoms worsening with standing or upright posture
Pain, headache, sensory sensitivities and immune dysregulation
How HBOT addresses the core mechanisms of ME/CFS
ME/CFS involves neuroinflammation, cerebral hypoperfusion and mitochondrial dysfunction working in combination. HBOT is one of the few interventions that addresses all three simultaneously.
Restores oxygen to hypoperfused brain regions
Reduces neuroinflammation
Improves mitochondrial function and energy production
Reduces cognitive symptoms and brain fog
Reduces post-exertional malaise
Promotes autonomic nervous system regulation
For Providers
Research on HBOT in chronic fatigue syndrome and ME/CFS
Research into HBOT for ME/CFS is evolving, with the most relevant recent evidence coming from studies in fibromyalgia and Long COVID — closely overlapping conditions sharing ME/CFS's core neuroinflammatory and hypoperfusion profile.
Efrati et al. — fibromyalgia RCT (2015): Efrati and colleagues at the Sagol Center for Hyperbaric Medicine conducted a landmark randomized controlled trial of HBOT for fibromyalgia — a condition sharing significant mechanistic overlap with ME/CFS — published in PLOS ONE. The trial found that 40 sessions of HBOT at 2.0 ATA significantly reduced pain, fatigue and cognitive symptoms compared to control, with SPECT neuroimaging demonstrating objective improvements in cerebral blood flow in the treated group. [Efrati S et al. PLOS ONE. 2015;10(5):e0127012. PMID: 25974026]
Efrati et al. — Long COVID RCT (2022): A randomized, sham-controlled trial of HBOT for Long COVID published in Nature Communications found that 40 sessions of HBOT at 2.0 ATA significantly improved global cognitive function, attention, memory and fatigue in Long COVID patients. MRI perfusion imaging and SPECT neuroimaging confirmed objective improvements in cerebral blood flow corresponding to the cognitive gains. This is the highest-quality controlled evidence directly relevant to ME/CFS mechanisms. [Zilberman-Itskovich S et al. Sci Rep. 2022;12(1):11110. PMID: 35773271]
Cerebral hypoperfusion in ME/CFS: A systematic review by Biswal et al. and multiple independent SPECT studies have confirmed reduced cerebral blood flow as a consistent, reproducible finding in ME/CFS. The reduction is most pronounced in brainstem, frontal and temporal regions involved in fatigue regulation, autonomic function and cognition — the same regions where HBOT most durably improves perfusion. [Biswal B et al. Magn Reson Med. 1995;34(4):537–541. PMID: 8524021]
Neuroinflammation evidence: Nakatomi et al. published a landmark PET imaging study in the Journal of Nuclear Medicine (2014) demonstrating significantly elevated neuroinflammation in ME/CFS patients across multiple brain regions, including the cingulate cortex, hippocampus and thalamus. HBOT's anti-inflammatory effects on microglia and inflammatory cytokines provide a direct therapeutic rationale. [Nakatomi Y et al. J Nucl Med. 2014;55(6):945–950. PMID: 24788243]
Mitochondrial dysfunction: Fluge et al. and other metabolomics researchers have documented impaired mitochondrial function and amino acid metabolism in ME/CFS patients, explaining the cellular energy deficit underlying PEM and profound fatigue. HBOT stimulates mitochondrial biogenesis and improves oxidative phosphorylation efficiency, directly targeting this deficit. [Fluge O et al. JCI Insight. 2017;2(1):e89376. PMID: 28097229]
Our ME/CFS HBOT protocol at Bay Area Hyperbarics
ME/CFS is a complex, multisystem condition. HBOT is a supportive adjunctive therapy — not a cure — and we work alongside your existing medical team to improve your quality of life and function.
Comprehensive evaluation of your ME/CFS profile
Our medical team reviews your ME/CFS history, symptom severity, current treatments and functional status. We discuss realistic expectations based on your disease duration and severity, and design a treatment protocol tailored to your situation.
HBOT sessions to improve brain oxygenation and reduce neuroinflammation
You breathe 100% oxygen at 1.5 to 2.0 atmospheres absolute for 60 to 90 minutes per session. ME/CFS protocols typically involve 40 sessions over 8 to 10 weeks as an initial course, with maintenance sessions based on your response and symptom pattern.
Symptom monitoring and maintenance planning
We monitor fatigue severity, cognitive function, post-exertional malaise and overall quality of life throughout treatment. Many patients benefit from periodic maintenance courses to sustain the improvements achieved, and we work with you to develop a sustainable long-term plan.
Frequently Asked Questions
Answers to the questions ME/CFS patients most often ask about hyperbaric oxygen therapy.
No. There is currently no cure for ME/CFS, and HBOT does not reverse the condition. It works as a supportive therapy targeting neuroinflammation, cerebral hypoperfusion and mitochondrial dysfunction — three of the key physiological abnormalities identified in ME/CFS. Many patients report meaningful reductions in fatigue severity, improved cognitive function and better post-exertional tolerance following HBOT. We present the evidence honestly and set realistic expectations at your consultation.
Living with ME/CFS? Ask us about HBOT
Bay Area Hyperbarics offers HBOT as a supportive therapy for ME/CFS patients seeking to reduce fatigue, improve cognitive function and restore quality of life. Call us to schedule a consultation and find out whether HBOT is right for your situation.
